ArticleClinical journal of gastroenterology2026
A case of duodenal metastasis from hepatocellular carcinoma.
Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An 82-year-old man underwent follow-up evaluations for a lung tumor in the right lower lobe in 2018. In 2019, computed tomography (CT) revealed an irregularly elevated tumor in liver segment S8, which was diagnosed as hepatocellular carcinoma (HCC) with inferior vena cava thrombus. Proton therapy was initially performed for the HCC. In 2020 and 2021, transcatheter arterial chemoembolization (TACE) was performed for liver recurrence. In 2022, CT showed a portal vein thrombus, lymph node metastasis from the pancreatic head tumor, and duodenal metastasis from HCC. The patient then underwent chemotherapy. During chemotherapy, transfusion and superior inferior pancreaticoduodenal artery embolization were performed for bleeding from duodenal metastasis. After chemotherapy, CT showed complete remission of the portal vein thrombus and lymph node metastasis. The duodenal metastasis had grown. In 2023, we performed subtotal gastric-sparing pancreaticoduodenectomy for duodenal metastasis. A pathological examination revealed duodenal metastasis from HCC and no exposure to the serosa, although there was some infiltration outside the muscularis propria. The patient remains well with no evidence of tumor recurrence 1 year after resection. We suggest that resection of duodenal metastases may not only control bleeding, but also improve the prognosis through local control.
Indexed as
Identifiers
40853534What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.